USA - NASDAQ:TBIO - US1920032000 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to TBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-11 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2021-08-04 | Roth Capital | Maintains | Neutral |
| 2021-08-03 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-08-03 | SVB Leerink | Maintains | Market Perform |
| 2021-07-26 | Roth Capital | Maintains | Buy |
| 2021-05-10 | SVB Leerink | Maintains | Market Perform |
| 2021-03-23 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-03-18 | SVB Leerink | Maintains | Outperform |
| 2021-03-18 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2021-03-18 | Roth Capital | Maintains | Buy |
| 2021-03-18 | Truist Securities | Downgrade | Buy -> Hold |
| 2021-03-18 | HC Wainwright & Co. | Maintains | Buy |
| 2021-03-01 | SVB Leerink | Maintains | Outperform |
7 analysts have analysed TBIO and the average price target is 4.08 USD. This implies a price increase of 26.32% is expected in the next year compared to the current price of 3.23.
The consensus rating for TELESIS BIO INC (TBIO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering TELESIS BIO INC (TBIO) is 7.